CD47 and osteosarcoma: An ongoing phase I clinical trial (NCT04751383) is testing the combination therapy of magrolimab (anti-CD47) and dinutuximab (anti-GD2) in patients with relapsed or refractory neuroblastoma or relapsed osteosarcoma.